论文部分内容阅读
目的研究玻璃体腔注射雷珠单抗(IVR)治疗有临床意义的黄斑水肿(CSME)及非临床意义的黄斑水肿(NCSME)患者的临床效果。方法将糖尿病黄斑水肿(DME)的患者77例,分为CSME组及NCSME组,行IVR治疗,比较治疗前后患者的最佳矫正视力(BCVA)和黄斑水肿最高高度。结果两组治疗1个月后,BCVA较治疗前差异均有统计学意义(P<0.05)。两组间比较,治疗前后各时间点黄斑水肿最高高度差异均无统计学意义(P>0.05)。结论 CSME及NCSME患者行IVR治疗后黄斑水肿高度降低,但黄斑水肿高度不能完全反映患者视力情况。
Objective To investigate the clinical effect of intravitreal injection of ranibizumab (IVR) in patients with clinically significant macular edema (CSME) and nonclinical macular edema (NCSME). Methods 77 patients with diabetic macular edema (DME) were divided into two groups: CSME group and NCSME group. IVR treatment was performed. The best corrected visual acuity (BCVA) and maximum height of macular edema were compared before and after treatment. Results After 1 month of treatment, the differences of BCVA between two groups were statistically significant (P <0.05). There was no significant difference in the maximum height of macular edema between the two groups before and after treatment (P> 0.05). Conclusion CSME and NCSME patients with high incidence of macular edema after IVR treatment, but the height of macular edema can not fully reflect the patient’s visual acuity.